SEC Tracker
Get the app

Synlogic SYBX

Synlogic Q2 FY26: revenue $0; diluted EPS −$0.04

Form
10-Q
Filed
Period
Importance
Notable

Key figures from this report

These are the numbers Synlogic reported for Q2 FY26, the quarter ended Jun 30, 2026, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

  1. Revenue$0Against $0 in Q2 FY2510-Q income statement, on EDGAR
  2. Net income−$543KAgainst −$529K in Q2 FY2510-Q income statement, on EDGAR
  3. Diluted EPS−$0.04Against −$0.04 in Q2 FY2510-Q income statement, on EDGAR
  4. Cash and cash equivalents$13.2M−23% from $17.0M in Q2 FY2510-Q balance sheet, on EDGAR
  5. Cash from operations−$922KAgainst −$399K in Q2 FY2510-Q cash flow statement, on EDGAR; the filing reports year-to-date cash flows; this quarter is the year-to-date total less the earlier quarters

Every quarter in the financial tables

View on EDGAR

Open in the app

Get an email when Synlogic files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Matinas BioPharma Holdings MTNB public float $5M, Jun 30, 2025
  2. China Pharma Holdings CPHI public float $4M, Jun 30, 2025
  3. Soligenix SNGX public float $5M, Jun 30, 2025
  4. Target Group CBDY public float $5M, Jun 30, 2025
  5. Creative Medical Technology Holdings CELZ public float $5M, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.